Controlled Drug Delivery Vehicles for Cancer Treatment and Their Performance

Overview

Journal Signal Transduct Target Ther

Specialties Cell Biology
Pharmacology

Date 2018 Mar 22

PMID 29560283

Citations 558

Authors

Sudipta Senapati

Arun Kumar Mahanta

Sunil Kumar

Pralay Maiti

Affiliations

Soon will be listed here.

Abstract

Although conventional chemotherapy has been successful to some extent, the main drawbacks of chemotherapy are its poor bioavailability, high-dose requirements, adverse side effects, low therapeutic indices, development of multiple drug resistance, and non-specific targeting. The main aim in the development of drug delivery vehicles is to successfully address these delivery-related problems and carry drugs to the desired sites of therapeutic action while reducing adverse side effects. In this review, we will discuss the different types of materials used as delivery vehicles for chemotherapeutic agents and their structural characteristics that improve the therapeutic efficacy of their drugs and will describe recent scientific advances in the area of chemotherapy, emphasizing challenges in cancer treatments.

Citing Articles

Forced intracellular degradation of xenoantigens as a modality for cell-based cancer immunotherapy.

Bikorimana J, Farah R, Abusarah J, Mandl G, Erregragui M, Goncalves M iScience. 2025; 28(3):111957.

PMID: 40060894 PMC: 11889607. DOI: 10.1016/j.isci.2025.111957.

Nanostructured Formulations for a Local Treatment of Cancer: A Mini Review About Challenges and Possibilities.

Amparo T, Almeida T, Sousa L, Xavier V, Silva G, Brandao G Pharmaceutics. 2025; 17(2).

PMID: 40006574 PMC: 11859672. DOI: 10.3390/pharmaceutics17020205.

Self-Assembled Protein-Polymer Nanoparticles via Photoinitiated Polymerization-Induced Self-Assembly for Targeted and Enhanced Drug Delivery in Cancer Therapy.

Ediriweera G, Chang Y, Yang W, Whittaker A, Fu C Molecules. 2025; 30(4).

PMID: 40005167 PMC: 11858777. DOI: 10.3390/molecules30040856.

Magnetic Nanoparticles and Drug Delivery Systems for Anti-Cancer Applications: A Review.

Graham W, Torbett-Dougherty M, Islam A, Soleimani S, Bruce-Tagoe T, Johnson J Nanomaterials (Basel). 2025; 15(4).

PMID: 39997849 PMC: 11858650. DOI: 10.3390/nano15040285.

Design and Synthesis of Mycophenolic Acid Analogues for Osteosarcoma Cancer Treatment.

Silalai P, Teeyakasem P, Pruksakorn D, Saeeng R ACS Bio Med Chem Au. 2025; 5(1):106-118.

PMID: 39990949 PMC: 11843339. DOI: 10.1021/acsbiomedchemau.4c00079.

References

Lee H, Lee E, Kim D, Jang N, Jeong Y, Jon S . Antibiofouling polymer-coated superparamagnetic iron oxide nanoparticles as potential magnetic resonance contrast agents for in vivo cancer imaging. J Am Chem Soc. 2006; 128(22):7383-9. DOI: 10.1021/ja061529k. View

Rasouli S, Davaran S, Rasouli F, Mahkam M, Salehi R . Synthesis, characterization and pH-controllable methotrexate release from biocompatible polymer/silica nanocomposite for anticancer drug delivery. Drug Deliv. 2013; 21(3):155-63. DOI: 10.3109/10717544.2013.838714. View

Mi P, Yanagie H, Dewi N, Yen H, Liu X, Suzuki M . Block copolymer-boron cluster conjugate for effective boron neutron capture therapy of solid tumors. J Control Release. 2017; 254:1-9. DOI: 10.1016/j.jconrel.2017.03.036. View

Kong S, Zhang W, Lee J, Brammer K, Lal R, Karin M . Magnetically vectored nanocapsules for tumor penetration and remotely switchable on-demand drug release. Nano Lett. 2010; 10(12):5088-92. DOI: 10.1021/nl1033733. View

Wadhwa R, Lagenaur C, Cui X . Electrochemically controlled release of dexamethasone from conducting polymer polypyrrole coated electrode. J Control Release. 2005; 110(3):531-41. DOI: 10.1016/j.jconrel.2005.10.027. View

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View

Ghosh R, Goswami U, Ghosh S, Paul A, Chattopadhyay A . Synergistic anticancer activity of fluorescent copper nanoclusters and cisplatin delivered through a hydrogel nanocarrier. ACS Appl Mater Interfaces. 2014; 7(1):209-22. DOI: 10.1021/am505799q. View

Huang N, Wang H, Zhao J, Lui H, Korbelik M, Zeng H . Single-wall carbon nanotubes assisted photothermal cancer therapy: animal study with a murine model of squamous cell carcinoma. Lasers Surg Med. 2010; 42(9):638-48. DOI: 10.1002/lsm.20968. View

Yavuz M, Cheng Y, Chen J, Cobley C, Zhang Q, Rycenga M . Gold nanocages covered by smart polymers for controlled release with near-infrared light. Nat Mater. 2009; 8(12):935-9. PMC: 2787748. DOI: 10.1038/nmat2564. View

10.

LaVan D, McGuire T, Langer R . Small-scale systems for in vivo drug delivery. Nat Biotechnol. 2003; 21(10):1184-91. DOI: 10.1038/nbt876. View

11.

Raynal I, Prigent P, Peyramaure S, Najid A, Rebuzzi C, Corot C . Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10. Invest Radiol. 2004; 39(1):56-63. DOI: 10.1097/01.rli.0000101027.57021.28. View

12.

Cao J, Wang R, Gao N, Li M, Tian X, Yang W . A7RC peptide modified paclitaxel liposomes dually target breast cancer. Biomater Sci. 2015; 3(12):1545-54. DOI: 10.1039/c5bm00161g. View

13.

Matsumura Y, Kataoka K . Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci. 2009; 100(4):572-9. PMC: 11158079. DOI: 10.1111/j.1349-7006.2009.01103.x. View

14.

Rogers W, Basu P . Factors regulating macrophage endocytosis of nanoparticles: implications for targeted magnetic resonance plaque imaging. Atherosclerosis. 2004; 178(1):67-73. DOI: 10.1016/j.atherosclerosis.2004.08.017. View

15.

Mamaeva V, Rosenholm J, Bate-Eya L, Bergman L, Peuhu E, Duchanoy A . Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of Notch signaling in cancer. Mol Ther. 2011; 19(8):1538-46. PMC: 3149161. DOI: 10.1038/mt.2011.105. View

16.

Pakunlu R, Wang Y, Saad M, Khandare J, Starovoytov V, Minko T . In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J Control Release. 2006; 114(2):153-62. DOI: 10.1016/j.jconrel.2006.06.010. View

17.

Kim T, Kim D, Chung J, Shin S, Kim S, Heo D . Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res. 2004; 10(11):3708-16. DOI: 10.1158/1078-0432.CCR-03-0655. View

18.

Song X, Wen Y, Zhu J, Zhao F, Zhang Z, Li J . Thermoresponsive Delivery of Paclitaxel by β-Cyclodextrin-Based Poly(N-isopropylacrylamide) Star Polymer via Inclusion Complexation. Biomacromolecules. 2016; 17(12):3957-3963. DOI: 10.1021/acs.biomac.6b01344. View

19.

Sun W, Gu Z . Engineering DNA scaffolds for delivery of anticancer therapeutics. Biomater Sci. 2015; 3(7):1018-24. DOI: 10.1039/c4bm00459k. View

20.

Huang C, Huang C, Mai F, Yen C, Tzing S, Hsieh H . Application of paramagnetic graphene quantum dots as a platform for simultaneous dual-modality bioimaging and tumor-targeted drug delivery. J Mater Chem B. 2020; 3(4):651-664. DOI: 10.1039/c4tb01650e. View